The PD-1/PD-L1 blockade can remove the inhibitory signals for T lymphocyte activation and increase the T cell's recognition of cancer cells damaged by drugs, thereby eradicating heterogeneous and drug-resistant cancer cells by long-term durable and systemic immune responses 20. Here, PDCD1 is linked to cancer.